Business
Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the latest data from eight hematologic malignancy clinical trials will be presented at the 2025 European Hematology Association (EHA) Congress and the 18th International Conference on Malignant Lymphoma (ICML). Notably, Dizal's two investigational drugs in lymphoma—golidocitinib and DZD8586—have collectively secured three oral presentation
About this update from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A
[{"type":"list","items":[{"val":[{"type":"text","content":"The latest 2-year follow-up data on golidocitinib as a maintenance therapy for peripheral T-cell lymphoma (PTCL) patients who achieved tumor response after first-line systemic therapy will be presented orally at the 2025 ICML","length":225,"tagName":"p"}]},{"val":[{"type":"text","content":"A pooled safety and efficacy analysis of two Phase I/II studies of DZD8586 in heavily pre-treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients has been selected for oral presentations at both 2025 ASCO and ICML","length":245,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":470,"olType":false},{"type":"text","content":"SHANGHAI, May 15, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the latest data from eight hematologic malignancy clinical trials will be presented at the 2025 European Hematology Association (EHA) Congress and the 18th International Conference on Malignant Lymphoma (ICML). Notably, Dizal's two investigational drugs in lymphoma—golidocitinib and DZD8586—have collectively secured three oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, EHA Congress and ICML.","length":644,"tagName":"p"},{"type":"image","alt":"Dizal logo (PRNewsfoto/Dizal Pharmaceutical)","displaySize":"","headline":null,"caption":"Dizal logo (PRNewsfoto/Dizal Pharmaceutical)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":153,"url":"https://media.zenfs.com/en/prnewswire.com/9e23c08c9c79c06f760f1f1494c86ccd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1u.Z_bHAhdSc0SaTeDpFdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI3MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9e23c08c9c79c06f760f1f1494c86ccd","width":400,"height":153}},"href":"https://mma.prnewswire.com/media/2084187/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Golidocitinib and DZD8586 are core assets in our hematologic malignancy pipeline. Accumulating clinical data continue to validate their clinical benefits to patients and attracted community's attention," said Xiaolin Zhang, PhD, CEO of Dizal.","length":257,"tagName":"p"},{"type":"text","content":"A high p...
More updates from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A